Neonc Technologies Holdings, INC 8-K filings

NeOnc Technologies Holdings, Inc. announced a $50 million strategic partnership with Quazar Investment for global expansion and clinical trials, alongside the acquisition of a cutting-edge AI and 3D bioprinting IP portfolio and the appointment of Dr. Ishwar K. Puri to its Board.

NeOnc Technologies Holdings, Inc. has entered into a binding letter of intent to acquire a to-be-formed limited liability company, including a key US patent, and will appoint Dr. Ishwar K. Puri to its Board of Directors.

NeOnc Technologies Holdings, Inc. executed a sub-license agreement with its Abu Dhabi subsidiary, NuroCure, marking a crucial step towards closing a $50 million strategic equity investment and MENA region expansion with Quazar Investment.

NeOnc Technologies Holdings, Inc. has secured $5 million in convertible promissory notes from unaffiliated accredited investors, featuring a 20% original issue discount and a conversion price at 80% of the lowest trading price.

NeOnc Technologies Holdings, Inc. has signed a non-binding term sheet with Quazar Investment for a $50 million equity investment to establish a new UAE-based platform for clinical trials and expansion into the Middle East and North Africa region.

NeOnc Technologies Holdings, Inc. announced the appointment of Dr. Josh Neman as Chief Clinical Officer, aiming to accelerate its four clinical trials, including lead asset NEO100, and bolster its FDA approval pathway.

NeOnc Technologies Holdings, Inc. has announced the appointment of Dr. Josh Neman, a distinguished neurobiology expert, as its new Chief Clinical Officer, effective June 5, 2025, signaling a strategic focus on advancing its intracranial malignancy treatments.

NeOnc Technologies Holdings, Inc. announced the retirement of its Chief Operating Officer, Patrick Walters, effective June 1, 2025.

NeOnc Technologies Holdings, Inc. appoints Executive Chairman Amir Heshmatpour as President to enhance leadership and drive strategic and clinical advancements.

NeOnc Technologies raises $1.6 million through a direct stock offering and partners with CBCC Global Research to broaden its clinical trial capabilities in India for neuro-oncology treatments.

NeOnc Technologies Holdings announces the resignation of Marcum LLP as its independent registered accounting firm and the engagement of CBIZ CPAs P.C., effective April 1, 2025.

NeOnc Technologies Holdings, a clinical-stage medical biotechnology company, announces the commencement of trading on the Nasdaq Global Market under the ticker symbol NTHI following the effectiveness of its registration statement for a direct listing.